Intelligence Report · ~12 min read

Amphastar Pharmaceuticals Intelligence Report

Generated from 1 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Jun 20, 2026

Confidence

Moderate Confidence · 72%

Evidence

6 items

Sources

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Amphastar Pharmaceuticals maintains an active intelligence profile across Neurology, Opioid Overdose. 1 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with low portfolio impact. Evidence coverage stands at 72% across 2 tracked sources. Highest-priority development: FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury. Regulatory precedent. Why this matters: sets a approval precedent in the same sub-indication (pain) as Amphastar Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

regulatory
FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
Regulatory precedent may inform portfolio positioning
View detail
regulatory
Investigational New Drug (IND) Application
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — REXTOVY (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 17 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: Low.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
High Confidence · 95%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Investigational New Drug (IND) Application
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — REXTOVY (SUPPL)
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

FDA Approves Supplemental Application for REXTOVY by Amphastar Pharmaceuticals
Neurology · Opioid Overdose

Executive Summary

Key Developments

FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury

Investigational New Drug (IND) Application

FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma

FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer

FDA AP — REXTOVY (SUPPL)